Neurovascular Unit Dysfunction In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The neurovascular unit (NVU) comprises endothelial cells, pericytes, smooth muscle cells, astrocytes, neurons, and extracellular matrix, working together to maintain blood-brain barrier (BBB) integrity and proper cerebral blood flow. Dysfunction of the NVU is increasingly recognized as a key contributor to neurodegenerative diseases.
| Property |
Value |
| Category |
Neurodegenerative Disease Mechanism |
| Key Components |
Endothelial cells, Pericytes, Astrocytes, Neurons, BBB |
| Associated Diseases |
Alzheimer's Disease, Parkinson's Disease, Vascular Cognitive Impairment |
| Pathological Features |
BBB breakdown, Pericyte loss, Reduced cerebral blood flow |
The cerebral endothelium forms the core of the BBB with:
- Tight junctions (claudins, occludin, ZO-1)
- Transport systems for nutrients
- Efflux pumps (P-glycoprotein)
- Low pinocytic activity
Pericytes play critical roles in:
- BBB development and maintenance
- Capillary stability
- Regulation of cerebral blood flow
- Stem cell-like regenerative capacity
- Neuroinflammation modulation
Astrocyte processes ensheath cerebral vessels:
- Regulate endothelial function
- Transport metabolites
- Maintain ion homeostasis
- Coordinate neurovascular coupling
BBB disruption occurs through:
- Tight junction degradation
- Matrix metalloproteinase (MMP) activation
- Pericyte loss and migration
- Reduced astrocyte support
- Leukocyte infiltration
Pericyte dysfunction leads to:
- Reduced capillary coverage
- Impaired CBF regulation
- BBB leakage
- Accumulation of toxic proteins
- Neuroinflammation
The ability to match blood flow to neural activity is compromised:
- Reduced astrocyte signaling
- Impaired nitric oxide signaling
- Endothelial dysfunction
- Neuronal energy failure
flowchart TD
A[Risk Factors] --> B[NVU Dysfunction] -->
B --> C[BBB Breakdown] -->
B --> D[Pericyte Loss)
B --> E[Reduced CBF] -->
C --> F[Toxin Accumulation] -->
C --> G[Leukocyte Entry] -->
D --> H[Protein Clearance Failure] -->
E --> I[Neuronal Energy Failure] -->
F --> J[Neuroinflammation)
G --> J
H --> J
I --> K[Cognitive Decline] -->
J --> K
K --> L[Neurodegeneration]
- VEGF Signaling: Altered angiogenesis, BBB permeability
- TGF-β Pathway: Pericyte function, fibrosis
- Notch Signaling: Angiogenesis, differentiation
- Wnt/β-catenin: BBB development, maintenance
- MMP Activation: Tight junction degradation
- BBB breakdown early in disease progression
- Pericyte loss correlates with cognitive decline
- Reduced cerebral blood flow
- Aβ clearance impairment across BBB
- Vascular contributions to amyloid deposition
- Nigral vasculature vulnerability
- BBB disruption in substantia nigra
- Reduced cerebral blood flow
- White matter lesions
- GBA-associated NVU dysfunction
- Primary NVU pathology
- Small vessel disease
- White matter hyperintensities
- Lacunar infarcts
- Chronic hypoperfusion
| Target |
Approach |
Status |
| Tight junction restoration |
MMP inhibitors |
Research |
| Pericyte protection |
Growth factors |
Research |
| CBF improvement |
Vasodilators |
Clinical trials |
| Aβ clearance |
BBB modulation |
Research |
| Neuroinflammation |
Anti-inflammatory |
Clinical trials |
The study of Neurovascular Unit Dysfunction In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12(12):723-738 MD, Sagare AP, Zlokovic.
- Sweeney BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133-150.
- Bell RD, Winkler EA, Sagare AP, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and in brain injury. Nat Med. 2014;20(4):409-421.
- Takano T, Han X, Deane R, et al. Two-photon imaging of astrocyte and pericyte interactions with the neurovascular unit. Nat Neurosci. 2007;10(11):1369-1376.
- Iadecola C. The neurovascular unit coming of age: a pathway to understanding Alzheimer disease. Stroke. 2016;47(7):1958-1966.
- Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015;85(2):296-302.
- Zhao Z, Nelson AR, Betsholtz C, et al. Establishment and dysfunction of the blood-brain barrier. Cell. 2015;163(5):1064-1078.
- Kisler K, Nelson AR, Montagne A, et al. Cerebral blood flow and the blood-brain barrier. Nat Neurosci. 2017;20(12):1623-1633.
- Yamazaki Y, Kanekiyo T. Blood-brain barrier dysfunction and the pathogenesis of Alzheimer's disease. Int J Mol Sci. 2017;18(9):1965.
- Profaci CP, Munji RN, Pulido RS, et al. The blood-brain barrier in health and disease: Important unanswered questions. J Exp Med. 2020;217(4):e20190062.
- van de Haar HJ, Burgmans S, Jansen JF, et al. Blood-brain barrier leakage in patients with early Alzheimer disease. Radiology. 2016;281(2):527-535.
- Janelidze S, Mattsson N, Stomrud E, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91(9):e867-e877.
- Nation DA, Sweeney MD, Montagne A, et al. Blood-brain barrier breakdown is an early marker of cognitive dysfunction in Alzheimer's disease. Nat Med. 2019;25(8):1218-1223.
- Yang AC, Stevens MY, Chen MB, et al. Physiological blood-brain transport is impaired with age in a mouse model. Nature. 2020;585(7823):117-126.
- Erdő F, Denes L, de Lange E. Age-associated physiological and pathological changes at the blood-brain barrier: A review. J Cereb Blood Flow Metab. 2017;37(1):4-24.
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
15 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
75% |
Overall Confidence: 45%